Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.68 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.64 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.63 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.63 |
| ▸ | BRAF | P15056 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | LCK | P06239 | 2/20 | 0.61 |
| ▸ | KIT | P10721 | 2/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2858703 | 0.90 | MAPT (0.70) | MEN1HTTRAB9AKMT2AKCNK3 | |
| SCHEMBL12858422 | 0.89 | MEN1 (0.73) | MEN1HTTRAB9AKMT2AKCNK3 | |
| SCHEMBL22025296 | 0.86 | PTGS1 (0.70) | MEN1HTTRAB9AKMT2AKCNK3 | |
| SCHEMBL2974812 | 0.86 | MEN1 (0.68) | MEN1HTTRAB9AKMT2AKCNK3 | |
| SCHEMBL30822434 | 0.86 | PTGS1 (0.70) | MEN1HTTRAB9AKMT2AKCNK3 | |
| SCHEMBL14468045 | 0.86 | MEN1 (0.68) | MEN1HTTRAB9AKMT2AKCNK3 | |
| SCHEMBL21479334 | 0.85 | MEN1 (0.67) | MEN1HTTRAB9AKMT2AKCNK3 | |
| SCHEMBL24249928 | 0.84 | MEN1 (0.70) | MEN1HTTRAB9AKMT2AKCNK3 | |
| SCHEMBL8363755 | 0.83 | MEN1 (0.77) | MEN1HTTRAB9AKMT2AKCNK3 | |
| SCHEMBL374471 | 0.83 | PTGS1 (0.70) | MEN1HTTRAB9AKMT2AKCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751136-B1 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC (US) | 2014-07-02 | — | — | EP | disclosed |
| EP-1751136-B1 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC (US) | 2014-07-02 | — | — | EP | disclosed |
| US-8476434-B2 | Protein kinase modulators and method of use | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476434-B2 | Protein kinase modulators and method of use | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476434-B2 | Protein kinase modulators and method of use | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110201602-A1 | PROTEIN KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201602-A1 | PROTEIN KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201602-A1 | PROTEIN KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-7880000-B2 | N-(5-(1,1- dimethylethyl)-3- isoxazolyl)-4-methyl-3- ((3-(4-pyrimidinyl)-2- pyridinyl)amino)benzamide, used for treating breast cancer or rheumatoid arthritis | AMGEN INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7880000-B2 | N-(5-(1,1- dimethylethyl)-3- isoxazolyl)-4-methyl-3- ((3-(4-pyrimidinyl)-2- pyridinyl)amino)benzamide, used for treating breast cancer or rheumatoid arthritis | AMGEN INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7880000-B2 | N-(5-(1,1- dimethylethyl)-3- isoxazolyl)-4-methyl-3- ((3-(4-pyrimidinyl)-2- pyridinyl)amino)benzamide, used for treating breast cancer or rheumatoid arthritis | AMGEN INC. (US) | 2011-02-01 | — | — | US | disclosed |
| EP-1751136-A2 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060009453-A1 | Protein kinase modulators and method of use | AMGEN INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005113494-A2 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009453-A1 | Protein kinase modulators and method of use | PHKG1, PRKCH, BMP2K | MEN1 3830/4885HTT 3739/4885RAB9A 1773/4885 |
| US-20110201602-A1 | PROTEIN KINASE MODULATORS AND METHOD OF USE | GRK4, MAP4K5, GRK5 | MEN1 4014/4885HTT 4284/4885RAB9A 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.